Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 2:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Nuclear Sclerotic Cataract
Interventions
Scheimpflug crystalline lens photographs
Procedure
Lead sponsor
Barnes Retina Institute
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Completed Not applicable Interventional Results available

Next Generation Cataract Surgery Study

NCT06071104
Conditions
Cataract
Interventions
Anterior segment ophthalmic surgery, UNITY VCS
Procedure · Device
Lead sponsor
Alcon Research
Industry
Eligibility
19 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
San Diego, California • Ventura, California • West Des Moines, Iowa + 1 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Beveled-Tip Versus(vs) Standard-Tip Vitrectomy Probe

NCT04076072
Conditions
Vitrectomy
Interventions
Utravit High-Speed 10000 cpm Beveled Probe, standard vitrector probe- Alcon (non-beveled) Ultravit 7500 cpm
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Epiretinal Membrane
Interventions
Immediate Vitrectomy, Deferred Vitrectomy
Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
47
States / cities
Scottsdale, Arizona • Glendale, California • Huntington Beach, California + 41 more
Completed Phase 4 Interventional Results available

Oral Versus Intravenous Sedation for Ocular Procedures

NCT03246724
Conditions
Surgery, Sedation
Interventions
Triazolam, Midazolam, Microcrystalline Cellulose, Sodium chloride 0.9%
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Proliferative Diabetic Retinopathy
Interventions
Macugen, Sham
Drug
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Choroideremia
Interventions
BIIB111
Genetic
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older · Male only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Baltimore, Maryland + 5 more
Conditions
Choroidal Melanoma
Interventions
1000CsK Silicon Oil Tamponade
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Cataract
Interventions
OMIDRIA (*Registered Product) {10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac}, Ketorolac Tromethamine {TORADOL} (0.5%) - Topical Eyedrop
Combination Product · Other
Lead sponsor
DHS Consulting
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Westbury, New York
Conditions
Retinitis Pigmentosa
Interventions
hRPC
Drug
Lead sponsor
ReNeuron Limited
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
3
States / cities
Phoenix, Arizona • Boston, Massachusetts • Portland, Oregon
Conditions
Retinal Detachment, Rhegmatogenous Retinal Detachment
Interventions
Lamivudine 300 MG, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Diabetic Retinopathy
Interventions
Ketorolac 0.45% ophthalmic solution, Placebo - Preservative-free artificial tears, Aqueous PGE2 and inflammatory cytokines measurements
Drug · Other
Lead sponsor
Stephen J. Kim, MD
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Phase 2 Interventional Results available

Bevacizumab Against Recurrent Retinal Detachment

NCT02192970
Conditions
Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Bevacizumab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Not listed Not applicable Interventional

Stem Cell Ophthalmology Treatment Study

NCT01920867
Conditions
Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease, Glaucoma
Interventions
RB (Retrobulbar), ST (Subtenon), IV (Intravenous), IVIT (Intravitreal), IO (Intraocular)
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Westport, Connecticut
Completed Phase 2Phase 3 Interventional Results available

Anti-VEGF vs. Prompt Vitrectomy for VH From PDR

NCT02858076
Conditions
Proliferative Diabetic Retinopathy, Vitreous Hemorrhage
Interventions
2-mg Intravitreous Aflibercept Injection, Prompt Vitrectomy Plus Panretinal Photocoagulation
Drug · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
60
States / cities
Campbell, California • Glendale, California • Huntington Beach, California + 50 more
Completed Not applicable Interventional Results available

iCare vs Tonopen vs Goldmann Applanation Post-vitrectomy Surgery

NCT01786954
Conditions
Intraocular Pressure
Interventions
Icare rebound tonometry, Tonopen applanation, Goldmann applanation
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Retinal Hemorrhage, Macular Degeneration
Interventions
vitrectomy with subretinal lucentis
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
50 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Royal Oak, Michigan
Conditions
Vitrectomy
Interventions
Vista Vitrectomy Probe
Device
Lead sponsor
VISTA Ophthalmics
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Bradenton, Florida • Bala-Cynwyd, Pennsylvania + 1 more
Conditions
Retina; Detachment, Rhegmatogenous
Interventions
Retina re-attachment repair using C3F8 gas tamponade
Device
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Prairie Village, Kansas
Conditions
Eye Diseases
Interventions
Next Generation Ophthalmic Irrigating Solution (NGOIS), BSS Plus
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Fort Worth, Texas
Completed No phase listed Observational

Vitreous Chemistry Analysis

NCT02051517
Conditions
Normal Volunteers
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Vitrectomy, Macular Pucker, Retinal Edema
Interventions
Dexamethasone Intracanalicular Insert, 0.4 mg, Prednisone acetate 1%
Drug
Lead sponsor
Kovach Eye Institute
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Elmhurst, Illinois
Recruiting Phase 4 Interventional Accepts healthy volunteers

Dropless Pars Plana Vitrectomy Study

NCT05331664
Conditions
Rhegmatogenous Retinal Detachment
Interventions
Pars plana vitrectomy, Triamcinolone Acetonide 40mg/mL, Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin, Prednisolone 1%, Atropine 1%
Procedure · Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Vitreomacular Adhesion
Interventions
Intravitreal Injection of sulfahexafluoride gas
Procedure
Lead sponsor
Northern California Retina Vitreous Associates
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Mountain View, California